Literature DB >> 8137251

Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.

Y Zou1, Y H Ling, N T Van, W Priebe, R Perez-Soler.   

Abstract

The lipophilic anthracycline antibiotic annamycin (Ann) was entrapped in liposomes of different size [median diameter: 1.64 microns, multilamellar liposomal Ann (L-Ann); 0.030 micron, small unilamellar Ann (S-Ann)] with > 90% entrapment efficiency and tested in vitro against four pairs of sensitive and multidrug-resistant (MDR) tumor cell lines and in vivo by the i.v. route in five tumor models: advanced s.c. B16 melanoma; s.c. M5076 reticulosarcoma; lung metastases of Lewis lung carcinoma; and s.c. KB and KB-V1 xenografts in nude mice. Predetermined optimal doses of the different formulations were used and the results were compared with doxorubicin (Dox). In vitro, Ann, either in suspension in 10% dimethyl sulfoxide (F-Ann) (1 mg/ml) or entrapped in liposomes, was able to partially overcome resistance in all four pairs of sensitive and MDR KB, 8226, P388, and CEM cell lines (resistance indexes 63, 269, 333, and 356 for Dox versus 4, 5, 19, and 8.7 for L-Ann, respectively). In vivo, both F-Ann and liposome-entrapped Ann were slightly more effective than Dox in inhibiting the growth of advanced s.c. B16 melanoma tumors. L-Ann was markedly more effective than Dox and moderately more effective than F-Ann in prolonging the life span of animals bearing s.c. M5076 and lung metastases of Lewis lung carcinoma tumors. All drugs were equally effective at optimal doses in delaying the growth of s.c. KB xenografts, whereas all Ann formulations were markedly more effective than Dox in delaying the growth of s.c. KB-V1 (MDR) xenografts. In all in vivo experiments, S-Ann was consistently more effective than L-Ann and L-Ann was more effective than F-Ann. These results indicate that (a) Ann is more effective than Dox by the i.v. route against several tumor models and that MDR tumors are partially not cross-resistant to Ann both in vitro and in vivo, (b) liposomes enhance the in vivo antitumor properties of Ann, and (c) small liposomes are more effective than large liposomes in enhancing Ann antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137251

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.

Authors:  Sameer Mahesh; Ashish Saxena; Xuan Qiu; Roman Perez-Soler; Yiyu Zou
Journal:  Clin Lung Cancer       Date:  2010-11-01       Impact factor: 4.785

Review 2.  From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.

Authors:  Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Nutr Food Res       Date:  2009-01       Impact factor: 5.914

3.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes.

Authors:  Narayanaswamy Subramanian; Archit Yajnik; Rayasa S Ramachandra Murthy
Journal:  AAPS PharmSciTech       Date:  2004-02-02       Impact factor: 3.246

Review 5.  Treatment of acute lymphoblastic leukaemia : a new era.

Authors:  Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis J Giles
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects.

Authors:  Xuan Qiu; Yuanxin Liang; Rani S Sellers; Roman Perez-Soler; Yiyu Zou
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

7.  Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Authors:  Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-25

Review 8.  Liposomal Formulations in Clinical Use: An Updated Review.

Authors:  Upendra Bulbake; Sindhu Doppalapudi; Nagavendra Kommineni; Wahid Khan
Journal:  Pharmaceutics       Date:  2017-03-27       Impact factor: 6.321

Review 9.  Advances and Challenges of Liposome Assisted Drug Delivery.

Authors:  Lisa Sercombe; Tejaswi Veerati; Fatemeh Moheimani; Sherry Y Wu; Anil K Sood; Susan Hua
Journal:  Front Pharmacol       Date:  2015-12-01       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.